thymidine has been researched along with Peripheral Nerve Diseases in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated the antiviral efficacy and safety of telbivudine in combination with pegylated interferon (PegIFN) alpha-2a in chronic hepatitis B (CHB) patients." | 9.20 | Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. ( Avila, C; Bao, W; Chuang, WL; Fainboim, H; Foster, GR; Gane, E; Lau, G; Lim, SG; Manns, M; Marcellin, P; Naoumov, N; Peng, CY; Rizzetto, M; Safadi, R; Trylesinski, A; Wedemeyer, H; Wursthorn, K, 2015) |
| "This study investigated the antiviral efficacy and safety of telbivudine in combination with pegylated interferon (PegIFN) alpha-2a in chronic hepatitis B (CHB) patients." | 5.20 | Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. ( Avila, C; Bao, W; Chuang, WL; Fainboim, H; Foster, GR; Gane, E; Lau, G; Lim, SG; Manns, M; Marcellin, P; Naoumov, N; Peng, CY; Rizzetto, M; Safadi, R; Trylesinski, A; Wedemeyer, H; Wursthorn, K, 2015) |
| "3'-Azido-2',3'-dideoxythymidine (AZT) has been administered to 7 patients with human immunodeficiency virus-associated neurological disease: 3 with dementia, 2 with peripheral neuropathy, 1 with dementia and peripheral neuropathy, and 1 with T-10 paraplegia." | 5.06 | Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease. ( Berg, G; Dalakas, M; Fischl, M; Grafman, J; Klecker, RW; McAtee, N; Perno, CF; Thomas, RV; Wichman, A; Yarchoan, R, 1988) |
| "Myopathy or neuropathy has been associated with lamivudine/telbivudine therapy in hepatitis B patients." | 3.80 | Lamivudine/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion. ( Jin, S; Lv, H; Wang, Z; Xu, H; Yuan, Y; Zhang, W; Zheng, L, 2014) |
| "Successful treatment of chronic hepatitis B (CHB) often requires long-term oral nucleoside/nucleotide agents which can be associated with viral resistance, patient non-compliance and adverse effects." | 2.46 | Safety evaluation of telbivudine. ( But, DY; Fung, J; Lai, CL; Yuen, MF, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (45.45) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Kripps, K | 1 |
| Nakayuenyongsuk, W | 1 |
| Shayota, BJ | 1 |
| Berquist, W | 1 |
| Gomez-Ospina, N | 1 |
| Esquivel, CO | 1 |
| Concepcion, W | 1 |
| Sampson, JB | 1 |
| Cristin, DJ | 1 |
| Jackson, WE | 1 |
| Gilliland, S | 1 |
| Pomfret, EA | 1 |
| Kueht, ML | 1 |
| Pettit, RW | 1 |
| Sherif, YA | 1 |
| Emrick, LT | 1 |
| Elsea, SH | 1 |
| Himes, R | 1 |
| Hirano, M | 1 |
| Van Hove, JLK | 1 |
| Scaglia, F | 1 |
| Enns, GM | 1 |
| Larson, AA | 1 |
| Marcellin, P | 1 |
| Wursthorn, K | 1 |
| Wedemeyer, H | 1 |
| Chuang, WL | 1 |
| Lau, G | 1 |
| Avila, C | 1 |
| Peng, CY | 1 |
| Gane, E | 1 |
| Lim, SG | 1 |
| Fainboim, H | 1 |
| Foster, GR | 1 |
| Safadi, R | 1 |
| Rizzetto, M | 1 |
| Manns, M | 1 |
| Bao, W | 1 |
| Trylesinski, A | 1 |
| Naoumov, N | 1 |
| Xu, H | 1 |
| Wang, Z | 1 |
| Zheng, L | 1 |
| Zhang, W | 1 |
| Lv, H | 1 |
| Jin, S | 1 |
| Yuan, Y | 1 |
| Moran, NF | 1 |
| Bain, MD | 1 |
| Muqit, MM | 1 |
| Bax, BE | 1 |
| But, DY | 1 |
| Yuen, MF | 1 |
| Fung, J | 1 |
| Lai, CL | 1 |
| Chanarin, I | 1 |
| Yarchoan, R | 1 |
| Thomas, RV | 1 |
| Grafman, J | 1 |
| Wichman, A | 1 |
| Dalakas, M | 1 |
| McAtee, N | 1 |
| Berg, G | 1 |
| Fischl, M | 1 |
| Perno, CF | 1 |
| Klecker, RW | 1 |
| Olsson, Y | 1 |
| Sjöstrand, J | 1 |
| Ono, K | 2 |
| Kato, S | 2 |
| Iwa, N | 2 |
| Doi, T | 2 |
| Naito, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open-label, Controlled, Multi-center Two-year Study Comparing Efficacy and Safety of Telbivudine, 600 mg PO in Combination With Peginterferon Alpha-2a sq 180 µg With Peginterferon Alpha-2a Monotherapy, and With Telbivudine Monotherapy in Tre[NCT00412750] | Phase 3 | 159 participants (Actual) | Interventional | 2006-12-31 | Terminated (stopped due to Enrollment stopped for safety issues) | ||
| The Safety, Tolerability, Pharmacodynamics, and Efficacy of Erythrocyte Encapsulated Thymidine Phosphorylase (EE-TP) in Patients With MNGIE[NCT03866954] | Phase 2 | 0 participants (Actual) | Interventional | 2024-11-30 | Withdrawn (stopped due to Change of circumstances with Commercial partner) | ||
| The Effect of Telbivudine on Renal Function and Proteinuria in Patients With Chronic Hepatitis B Infection and Chronic Kidney Diseases[NCT02049736] | 0 participants (Actual) | Interventional | 2013-12-31 | Withdrawn (stopped due to unable to recruit patients) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change from baseline in HBV DNA concentration at Weeks 12 and 24 was analyzed using an analysis of covariance (ANCOVA) model with baseline HBV DNA concentration (log10 copies/ml) as a covariate, treatment and country as factors. (NCT00412750)
Timeframe: Weeks 12 and 24
| Intervention | log 10 copies/ml (Least Squares Mean) | |
|---|---|---|
| Week 12 (n= 37, 52, 50) | Week 24 (n= 17, 48, 42) | |
| LdT + PEG-INF | -6.0569 | -6.9187 |
| LdT Monotherapy | -5.1658 | -5.9633 |
| PEG-INF Monotherapy | -1.8991 | -2.4513 |
The percentage of participants with Virologic breakthrough at Week 48 and 52 by treatment. For the subgroup of patients on treatment who achieve HBV DNA >= 1 log10 copies/mL reduction from baseline on 2 consecutive visits, Virologic Breakthrough is defined as HBV DNA >= 1 log10 copies/mL from nadir on two consecutive visits. (NCT00412750)
Timeframe: Weeks 48 and 52
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Virologic breakthrough Week 48 | Virologic breakthrough Week 52 | |
| LdT + PEG-INF | 0.0 | 0.0 |
| LdT Monotherapy | 5.7 | 7.5 |
| PEG-INF Monotherapy | 7.5 | 9.4 |
The percentage of participants who achieved HBV DNA non-detectability using the COBAS Amplicor HBV Monitor assay utilizing polymerase chain reaction (PCR) (threshold for detection 300 copies/mL) and Alanine aminotransferase (ALT) normalization defined as ALT within normal limits on two successive visits for a patient with an elevated ALT (>1.0 x upper limit normal) at baseline summarized at Weeks 12 and 24. (NCT00412750)
Timeframe: Weeks 12 and 24
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| HBV DNA non-detectability Week 12 (n=37,52,50) | ALT normalization Week 12 (n=37,52,50) | HBV DNA non-detectability Week 24 (n=17,48,42) | ALT normalization Week 24 (n=17,48,41) | |
| LdT + PEG-INF | 13.5 | 13.5 | 70.6 | 11.8 |
| LdT Monotherapy | 9.6 | 28.8 | 35.4 | 54.2 |
| PEG-INF Monotherapy | 0.0 | 20.0 | 7.1 | 31.7 |
HBeAg loss is defined as the loss of detectable serum HBeAg in a patient who was HBeAg positive at baseline. HBeAg seroconversion is defined as HBeAg loss with detectable Hepatitis B 'e' antibody (HBeAb). The efficacy was assessed for 18 weeks, 24 weeks, 48 weeks, 52 weeks and on treatment completion (TC). (NCT00412750)
Timeframe: Weeks 18, 24, 48, 52 and Treatment completion (TC)
| Intervention | Percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HBeAg loss Week 18 (n=28,51,45) | HBeAg seroconversion Week 18 (n=28,51,45) | HBeAg loss Week 24 (n=17,48,42) | HBeAg seroconversion Week 24 (n=17,48,42) | HBeAg loss Week 48 (n=0,19,12) | HBeAg seroconversion Week 48 (n=0,19,12) | HBeAg loss Week 52 (n=0,10,6) | HBeAg seroconversion Week 52 (n=0,10,6) | HBeAg loss TC (n=14,24,9) | HBeAg seroconversion TC (n=14,24,9) | |
| LdT + PEG-INF | 17.9 | 17.9 | 17.6 | 7.6 | NA | NA | NA | NA | 7.1 | 7.1 |
| LdT Monotherapy | 7.8 | 7.8 | 6.3 | 4.2 | 36.8 | 36.8 | 50.0 | 50.0 | 29.2 | 25.0 |
| PEG-INF Monotherapy | 8.9 | 8.9 | 11.9 | 11.9 | 25.0 | 25.0 | 16.7 | 16.7 | 33.3 | 33.3 |
2 reviews available for thymidine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Safety evaluation of telbivudine.
Topics: Adult; Antiviral Agents; Biomarkers; Creatine Kinase; Double-Blind Method; Drug Resistance, Viral; F | 2010 |
The effects of nitrous oxide on cobalamins, folates, and on related events.
Topics: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Adult; Analgesia; Animals; Carbon; Cell D | 1982 |
2 trials available for thymidine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Carriers; Drug Therapy, Combination; Female; Global Health | 2015 |
Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Clinical Trials as Topic; Dementia; Humans; Male; M | 1988 |
7 other studies available for thymidine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Successful liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).
Topics: Adolescent; Adult; Esophageal Motility Disorders; Exome Sequencing; Female; Hematopoietic Stem Cell | 2020 |
Lamivudine/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion.
Topics: Adult; Aged, 80 and over; Antiviral Agents; Biopsy; DNA, Mitochondrial; Female; Hepatitis B; Humans; | 2014 |
Carrier erythrocyte entrapped thymidine phosphorylase therapy for MNGIE.
Topics: Adult; Deoxyuridine; Drug Delivery Systems; Erythrocyte Transfusion; Erythrocytes; Fatal Outcome; Fe | 2008 |
Telbivudine: rhabdomyolysis and neuropathy.
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Nucleosides; Peripheral Nervous System Diseases; Pyr | 2010 |
Proliferation of mast cells in peripheral nerves during Wallerian degeneration. A radioautographic study.
Topics: Animals; Autoradiography; Cell Division; Cell Nucleus; DNA; Mast Cells; Nerve Degeneration; Neurons; | 1969 |
Autoradiographic and cytochemical studies on nuclear and cytoplasmic inclusions of duck embryo fibroblasts infected with herpes type virus isolated from chickens with Marek's disease.
Topics: Animals; Autoradiography; Avian Leukosis; Cell Nucleus; Chickens; Cytoplasmic Granules; Ducks; Embry | 1970 |
Isolation of herpes type virus from chickens with Marek's disease using duck embryo fibroblast cultures.
Topics: Animals; Avian Leukosis; Chickens; Culture Techniques; Cytopathogenic Effect, Viral; DNA, Viral; Duc | 1970 |